Orexo starts to test modia on patients in collaboration with ApexB.io and Magellan Rx Management 1 - The medication-assisted treatment (MAT) of opioid use disorder (OUD) requires a combination of drug and therapy treatment, where access and quality of counselling and psychosocial support are one of the main barriers to successful treatment - modia can help those with OUD by providing access to an evidence-based digital therapy rooted in cognitive behavioral techniques UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.